MIT STARTUP EXCHANGE FEBRUARY 2025 DEMO DAY
February 27, 2025
Viniyak Ramesh Co-Founder and Chief Customer Officer Ikigai Labs
Turning CO2 into Carbon-Neutral Industrial Chemicals Evan Haas, Co-Founder & CEO, Helix Carbon Helix Carbon: https://helixcarbon.co/
Helix Carbon is decarbonizing heavy industry by transforming emitted CO2 into carbon-neutral fuels & chemicals including CO, ethylene, and syngas. Born from MIT innovations, these electrochemical systems use inexpensive catalysts with high stability to convert flue gas directly into these cost-competitive carbon feedstocks. Helix builds drop-in electrolyzers that integrate with existing direct reduced iron & petrochemical facilities to upcycle CO2 emissions into chemical feedstocks, enabling green steel, polycarbonate, polyurethane, and more.
CSAIL members, Underscore VC, are holding an ADDITIONAL info session just for our community to talk about their Summer Fellows Program.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.